HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Asks Whether Supplement Industry Has Outgrown Regulatory Framework

Executive Summary

Commissioner Gottlieb appointed working group at FDA to evaluate agency's existing structure and strategies for oversight of supplement sector. Group's findings will determine extent of potential changes in regulatory authorities agency will ask members of Congress to establish through legislation. Action plan expected in early 2019.

You may also be interested in...



Modernizing FDA's Supplement Industry Regulation Mapped Out In Five-Point Plan

Commissioner Scott Gottlieb announces FDA's plan for policy changes to implement "one of the most significant modernizations of dietary supplement regulation and oversight in more than 25 years." Plan includes steps to ensure its regulatory framework is flexible enough to adequately evaluate product safety while also promoting innovation, particularly finalizing NDI notifications guidance and fostering submissions of the notifications.

FDA Regulatory Oversight No Impediment To Drug-Spiked Supplements, Study Finds

Products marketed for sexual enhancement or weight loss remain the most common types that contain undeclared drug ingredients,but drugs are showing up less in a third type that had been frequently found with drugs, bodybuilding supplements, says study in Journal of the American Medical Association. Researchers analyzing FDA database of tainted products marketed as supplements, say the trend didn't slow as FDA increased its GMP inspections and issued numerous warning letters.

'Big Shoes To Fill' As Hatch Retirement Leaves Supplement Market Legacy

Sen. Orrin Hatch won’t seek re-election and will leave 24 years after Congress passed the Dietary Supplement Health and Education Act as a framework for FDA's regulation of vitamin, mineral and supplement product manufacturing and marketing. Hatch is in his seventh term and is the longest-serving Senate member.

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel